StockData
Aytu BioPharma, Inc logo

Aytu BioPharma, Inc (AYTU) stock

AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.00 (0.00%)

Close on Nov 18, 2026Market cap $28.91MP/E –Yield –

Aytu BioPharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Aytu BioPharma's operating income for the twelve months ending Jun 30, 2026 was -$8.32M. For fiscal 2026 it was -$8.32M. The highest annual figure on record is -$52.41K in fiscal 2013.

Annual operating income

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$8.32M–
FY2025Jun 30, 2025-$7.83M–
FY2024Jun 30, 2024-$1.59M–
FY2023Jun 30, 2023-$17.07M–
FY2022Jun 30, 2022-$109.91M–
FY2021Jun 30, 2021-$58.87M–
FY2020Jun 30, 2020-$21.13M–
FY2019Jun 30, 2019-$16.85M–
FY2018Jun 30, 2018-$19.70M–
FY2017Jun 30, 2017-$20.13M–
FY2016Jun 30, 2016-$21.70M–
FY2015Jun 30, 2015-$7.63M–
FY2013Aug 31, 2013-$52.41K–
FY2012Aug 31, 2012-$56.36K–
FY2011Aug 31, 2011-$133.62K–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026-$777.00K–
Q3 FY2026CQ1 2026Mar 31, 2026-$4.06M-267.9%
Q2 FY2026CQ4 2025Dec 31, 2025-$1.97M–
Q1 FY2026CQ3 2025Sep 30, 2025-$1.50M–
Q4 FY2025CQ2 2025Jun 30, 2025-$7.62M–
Q3 FY2025CQ1 2025Mar 31, 2025$2.42M–
Q2 FY2025CQ4 2024Dec 31, 2024-$1.70M-153.9%
Q1 FY2025CQ3 2024Sep 30, 2024-$930.00K–
Q4 FY2024CQ2 2024Jun 30, 2024-$2.27M-1445.0%
Q3 FY2024CQ1 2024Mar 31, 2024-$1.60M–
Q2 FY2024CQ4 2023Dec 31, 2023$3.15M–
Q1 FY2024CQ3 2023Sep 30, 2023-$867.00K–
Q4 FY2023CQ2 2023Jun 30, 2023$169.00K–
Q3 FY2023CQ1 2023Mar 31, 2023-$8.56M–
Q2 FY2023CQ4 2022Dec 31, 2022-$6.87M–
Q1 FY2023CQ3 2022Sep 30, 2022-$1.81M–
Q4 FY2022CQ2 2022Jun 30, 2022-$16.94M–
Q3 FY2022CQ1 2022Mar 31, 2022-$53.42M–
Q2 FY2022CQ4 2021Dec 31, 2021-$11.29M–
Q1 FY2022CQ3 2021Sep 30, 2021-$27.70M–
Q4 FY2021CQ2 2021Jun 30, 2021-$24.07M–
Q3 FY2021CQ1 2021Mar 31, 2021-$25.67M–
Q2 FY2021CQ4 2020Dec 31, 2020-$5.58M–
Q1 FY2021CQ3 2020Sep 30, 2020-$3.56M–
Q4 FY2020CQ2 2020Jun 30, 2020-$6.63M–
Q3 FY2020CQ1 2020Mar 31, 2020-$4.79M–
Q2 FY2020CQ4 2019Dec 31, 2019-$4.97M–
Q1 FY2020CQ3 2019Sep 30, 2019-$4.74M–
Q4 FY2019CQ2 2019Jun 30, 2019-$4.58M–
Q3 FY2019CQ1 2019Mar 31, 2019-$4.30M–
Q2 FY2019CQ4 2018Dec 31, 2018-$4.55M–
Q1 FY2019CQ3 2018Sep 30, 2018-$3.42M–
Q4 FY2018CQ2 2018Jun 30, 2018-$3.83M–
Q3 FY2018CQ1 2018Mar 31, 2018-$7.52M–
Q2 FY2018CQ4 2017Dec 31, 2017-$3.99M–
Q1 FY2018CQ3 2017Sep 30, 2017-$4.36M–
Q4 FY2017CQ2 2017Jun 30, 2017-$5.10M–
Q3 FY2017CQ1 2017Mar 31, 2017-$4.86M–
Q2 FY2017CQ4 2016Dec 31, 2016-$4.20M–
Q1 FY2017CQ3 2016Sep 30, 2016-$5.97M–

More Aytu BioPharma figures

See a number that looks wrong?